scanX
Home
Strides Pharma Science

Strides Pharma Science

636.90
+8.45
(1.34%)
Market Cap
5,869.84 Cr
EPS
-7.76
PE Ratio
22.23
Dividend Yield
0.40 %
Industry
Healthcare
52 Week High
1,675.00
52 Week low
301.13
PB Ratio
2.53
Debt to Equity
1.28
Add Ratio
Live Chart

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy100.00 %
100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %

Peer Comparison Compare Peers on Screener

Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
Sun Pharmaceutical
 1,669.30 4,00,520.99 34.13 49,887.20 12.06 9,648 13.77 37.74
Divis Laboratories
 5,978.30 1,58,705.08 76.14 8,184.00 0.89 1,600 64.53 51.57
Cipla
 1,479.70 1,19,502.65 23.70 26,520.70 14.17 4,155 47.38 51.15
Torrent Pharmaceuticals
 3,095.95 1,04,781.02 56.64 10,785.70 11.59 1,656 13.54 45.77
Dr Reddys Laboratories
 1,170.95 97,705.34 18.09 28,905.40 12.36 5,578 1.69 30.83
Mankind Pharma
 2,348.45 96,889.27 47.77 10,615.60 19.57 1,942 -16.38 39.42
Zydus Life Science
 899.65 90,525.84 19.78 19,831.50 13.82 3,831 29.92 36.77
Lupin
 1,977.50 90,213.07 31.46 20,141.50 19.94 1,936 38.82 38.83
Aurobindo Pharma
 1,121.25 65,122.38 18.72 29,559.20 17.55 3,169 -10.04 42.81
Abbott
 29,429.65 62,535.95 47.37 6,097.20 10.80 1,201 16.01 61.56
Growth Rate
Revenue Growth
8.26 %
Net Income Growth
-35.69 %
Cash Flow Change
1,478.63 %
ROE
-32.55 %
ROCE
-1,066.67 %
EBITDA Margin (Avg.)
39.00 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
314
613
729
856
980
815
931
897
802
692
791
805
1,266
478
530
862
662
696
842
760
641
839
834
845
922
702
744
805
952
954
954
933
1,014
939
1,035
1,075
1,071
1,100
1,195
1,160
Expenses
274
564
628
728
855
676
730
602
577
595
688
627
604
448
496
516
572
612
610
574
772
648
662
712
773
850
818
833
944
1,002
844
892
879
802
1,054
886
911
886
987
946
EBITDA
40
50
101
128
125
140
201
295
225
97
103
178
663
30
34
346
90
84
232
187
-131
191
173
133
149
-148
-75
-28
8
-49
110
41
135
136
-18
189
160
214
209
215
Operating Profit %
11 %
3 %
7 %
13 %
8 %
14 %
16 %
17 %
15 %
10 %
11 %
16 %
10 %
5 %
5 %
10 %
7 %
11 %
15 %
22 %
-25 %
17 %
17 %
14 %
15 %
-23 %
-13 %
-5 %
-9 %
-7 %
6 %
-3 %
11 %
14 %
-5 %
12 %
16 %
19 %
15 %
18 %
Depreciation
20
32
36
40
39
42
44
31
38
35
37
38
44
29
31
28
30
43
42
44
45
49
53
53
52
55
57
61
61
60
62
60
61
60
60
49
50
49
49
48
Interest
15
28
34
54
62
56
58
44
48
52
49
50
46
17
17
22
23
35
40
40
40
37
37
35
42
42
44
42
50
55
68
58
81
76
79
70
80
80
74
52
Profit Before Tax
33
19
69
68
24
41
98
220
140
10
17
90
573
-16
-14
296
37
6
149
104
-217
105
83
46
55
-244
-175
-131
-103
-163
-20
-78
-7
0
-157
70
30
85
86
114
Tax
22
9
34
10
20
9
13
24
8
4
5
2
-5
-14
-6
-0
-8
3
7
11
-11
3
6
11
12
-36
-7
-5
-132
-28
-38
4
7
10
-7
16
19
17
14
24
Net Profit
11
10
35
58
4
33
85
196
132
6
12
88
578
-3
-9
296
45
3
142
92
-207
102
77
35
44
-209
-168
-127
29
-135
19
-82
-14
-9
-150
54
10
68
72
90
EPS in ₹
1.91
1.34
4.44
6.59
1.74
2.91
8.29
20.96
12.57
0.06
0.96
9.55
63.56
-0.48
-1.34
32.77
5.31
0.41
15.94
10.48
-22.77
11.56
9.03
4.22
5.14
-22.88
-18.12
-13.55
3.25
-15.13
2.54
-8.86
-1.06
-0.79
-14.54
5.43
1.98
7.64
7.81
9.56
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
2,475
7,659
8,105
6,708
7,980
6,152
7,015
6,976
6,638
5,840
Fixed Assets
701
2,499
2,980
2,977
3,648
2,099
2,219
2,347
2,311
1,865
Current Assets
1,429
3,595
3,792
2,484
3,049
2,372
2,817
3,362
3,243
2,969
Capital Work in Progress
171
1,200
780
620
453
413
447
291
151
162
Investments
561
1,260
1,525
588
702
549
697
540
490
303
Other Assets
1,041
2,700
2,821
2,524
3,177
3,091
3,651
3,798
3,687
3,510
Total Liabilities
2,475
7,659
8,105
6,708
7,980
6,152
7,015
6,976
6,638
5,840
Current Liabilities
1,020
1,940
3,104
1,899
2,662
2,545
2,738
3,412
2,990
2,879
Non Current Liabilities
291
2,813
2,119
2,191
2,516
1,012
1,463
1,181
1,475
889
Total Equity
1,164
2,906
2,882
2,618
2,802
2,595
2,814
2,383
2,173
2,072
Reserve & Surplus
1,085
2,774
2,659
2,374
2,559
2,438
2,687
2,269
2,105
2,034
Share Capital
60
89
89
90
90
90
90
90
90
92
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-288
812
-596
-259
110
-184
-56
45
133
-143
Investing Activities
50
-2,205
-1,222
570
-145
1,321
-522
-119
302
-150
Operating Activities
83
73
288
187
60
205
481
-258
44
701
Financing Activities
-421
2,944
338
-1,016
194
-1,709
-16
421
-214
-693
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
29.67 %
29.62 %
29.60 %
29.60 %
30.60 %
30.37 %
31.07 %
30.89 %
28.27 %
28.07 %
27.78 %
27.39 %
25.88 %
25.86 %
25.84 %
26.82 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.05 %
0.05 %
0.05 %
0.05 %
0.00 %
0.00 %
24.57 %
26.71 %
30.08 %
28.48 %
DIIs
14.82 %
13.23 %
14.22 %
14.85 %
12.40 %
9.82 %
13.59 %
18.84 %
18.29 %
20.00 %
18.22 %
17.56 %
18.04 %
18.56 %
18.24 %
16.92 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
14.01 %
16.64 %
17.89 %
20.42 %
21.82 %
22.29 %
22.40 %
22.43 %
25.51 %
24.93 %
23.39 %
22.65 %
21.19 %
20.87 %
18.57 %
20.86 %
Others
41.49 %
40.51 %
38.29 %
35.12 %
35.19 %
37.51 %
32.88 %
27.77 %
27.86 %
26.93 %
30.60 %
32.39 %
10.32 %
8.00 %
7.26 %
6.90 %
No of Share Holders
74,074
96,976
1,06,927
1,25,553
1,33,190
1,34,718
1,30,682
1,23,964
1,20,916
1,12,775
1,01,638
91,182
84,695
91,917
96,009
1,14,237

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 2 3 0.00 0.00 0.00 0.00 2.5 0.00
Dividend Yield (%) 0.00 0.00 0.42 0.93 0.00 0.00 0.00 0.00 0.39 0.00

Corporate Action

Announcements

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
1 day ago
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 days ago
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
3 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Feb 04, 2025, 15:19
Announcement under Regulation 30 (LODR)-Newspaper Publication
Jan 31, 2025, 17:24
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 30, 2025, 18:26
Integrated Filing (Financial)
Jan 30, 2025, 16:38
Announcement under Regulation 30 (LODR)-Change in Registered Office Address
Jan 30, 2025, 13:31
Announcement under Regulation 30 (LODR)-Change in Directorate
Jan 30, 2025, 13:30
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 30, 2025, 13:27
Board Meeting Outcome for Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended December 31 2024
Jan 30, 2025, 13:24
Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended December 31 2024
Jan 30, 2025, 13:21
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 24, 2025, 19:59
Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Jan 24, 2025, 18:45
Onesource Specialty Pharma Limited (Onesource) - IndiaS First Specialty Pharma CDMO Receives Listing And Trading Approval For Its Equity Shares From BSE And NSE. Onesource To Start Trading In NSE
Jan 23, 2025, 11:06
Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Globals Corporate Sustainability Assessment (CSA) 2024
Jan 22, 2025, 11:05
Intimation About Receipt Of Order On Jan 20 2024 From The Transfer Pricing Officer Being Issued Under Section 92 CA (3) Of Income Tax Act 1961 For AY 22-23
Jan 21, 2025, 18:52
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 20, 2025, 14:50
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dec 27, 2024, 15:53

Technical Indicators

Bearish
0
Neutral
0
Bullish
0
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Price & Volume Screeners
Fundamental Screeners
Technical Screeners
Candlestick Screeners
Intraday Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 Moneylicious Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Corporate Office: A-302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai – 400066, Maharashtra, India. Land Line: 022-43116666.